You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Moderna料今年新冠疫苗销售达184亿美元 正研发变种病毒加强版疫苗
阿思达克 02-26 15:11
《路透》报道,美国药厂莫德纳(Moderna)(MRNA.US)表示,预计今年新冠疫苗销售达184亿美元,使集团自2010年成立以来首次录得盈利。

莫德纳及辉瑞(PFE.US)为仅有两家药企目前获美国批准紧急使用其研发的新冠疫苗。莫德纳执行长Stephane Bancel表示,集团一直在提高产能,预计今年将生产7亿至10亿剂疫苗。而集团亦在研发针对南非变种病毒的加强版疫苗,且已将疫苗交给美国国家卫生研究院(NIH)用於临床试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account